The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.
RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.
The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.
GLA may help with hair loss due to its anti-inflammatory properties and 5ar enzyme inhibition. It's considered potentially more important than biotin, especially for those already using finasteride and dutasteride.
RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Foligain's DHT blocker is criticized for not effectively blocking DHT, with users labeling it as ineffective and overpriced. Minoxidil is mentioned as the only legitimate product in their lineup.
The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.
Significant hair regrowth was achieved using RU58841, minoxidil, and microneedling during a high-dose steroid cycle. The user reported no side effects from RU58841 and plans to continue the regimen.
The conversation discusses the potential of kintor pyrilutamide as a promising treatment for hair loss, with ongoing trials in various phases. There is skepticism due to delays in trial results, but the company is actively pursuing further trials.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
New hair loss treatments like GT20029, Clascoterone, and PP405 are being discussed, with concerns about how to apply multiple topicals alongside existing treatments like minoxidil and finasteride. Suggestions include creating a routine, mixing treatments, or minimizing redundancy in treatment stacks.
Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.
Hair loss may be influenced by mechanical tension and inflammation, with the hi-c5 protein amplifying androgen effects, leading to follicle miniaturization. Treatments like finasteride, minoxidil, and scalp massages are suggested to manage hair loss.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
The conversation is about hair loss treatments, specifically discussing GHK-Cu, with some users suggesting Minoxidil as more effective. OP is looking for a GHK-Cu product available in Europe.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.
Dutasteride, Minoxidil, dermarolling, and Nizoral are used for hair improvement, with positive results reported. LGD-4033 is being used alongside these treatments, with no negative impact on hair and some users reporting reduced shedding.
A user is questioning the authenticity of a cheaper RU58841 product compared to other brands. Another user explains that RU58841 is a research chemical and suggests caution when purchasing such products.
Using a face serum with 1% copper peptides (ghk-cu) on the scalp as an adjunct to finasteride and minoxidil for hair growth and scalp health. The user is unable to find a specific hair serum with ghk-cu locally.